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Abstract
The leaves of the white mulberry tree (Morus alba L.) are used worldwide in traditional medicine as anti-diabetics. Various
constituents of mulberry leaves, such as iminosugars (i.e. 1-deoxynojirimicin), flavonoids and related compounds,
polysaccharides, glycopeptides and ecdysteroids, have been reported to exert anti-diabetic activity, but knowledge about
their contribution to the overall activity is limited. The objective of the present work was to determine the in vivo anti-
diabetic activity of an extract of mulberry leaves (MA), and to examine to what extent three major constituents, chlorogenic
acid, rutin and isoquercitrin, might contribute to the observed activity. Quantities of the three constituents of interest in the
extract were determined by using HPLC-DAD. Activity was determined by using a type II diabetic rat model. After 11 days of
per os administration of 250 or 750 mg/kg of MA or the corresponding amounts of each individual compound, a dose
dependent decrease of non-fasting blood glucose levels were found for MA, chlorogenic acid and rutin, but not for
isoquercitrin. Based on our results, chlorogenic acid and rutin might account for as much as half the observed anti-diabetic
activity of MA, hence they can be considered as excellent markers for the quality control of mulberry products.
Citation: Hunyadi A, Martins A, Hsieh T-J, Seres A, Zupko´ I (2012) Chlorogenic Acid and Rutin Play a Major Role in the In Vivo Anti-Diabetic Activity of Morus alba
Leaf Extract on Type II Diabetic Rats. PLoS ONE 7(11): e50619. doi:10.1371/journal.pone.0050619
Editor: Bridget Wagner, Broad Institute of Harvard and MIT, United States of America
Received August 24, 2012; Accepted October 23, 2012; Published November 21, 2012
Copyright:  2012 Hunyadi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was carried out within the framework of COST Action CM0804, Chemical Biology with Natural Products. The project was supported by the
Hungarian National Research Fund (OTKA PD75383), the New Hungary Development Plan (TA´MOP-4.2.1/B-09/1/KONV-2010–0005), the Baross Ga´bor Program
(MFB-00339/2010) and by the grant from the National Science Council of Taiwan (NSC 982314B037011MY3). AM was supported by the Fundac¸a˜o para a Cieˆncia e
para a Tecnologia, Portugal, with the grant SFRH/BPD/81118/2011. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hunyadi.a@pharm.u-szeged.hu
Introduction
In the last decades, diabetes has become a major health problem
both in developed and in developing countries. Moreover,
projections for its prevalence seem to be less and less optimistic.
In 2000 there were around 171 million of diabetic people and an
increase to 366 million was estimated for 2030 [1]. Data from
2010, however, showed that prevalence increased to ca. 285 mil-
lion and 439 million affected adults are now expected till 2030 [2].
Type 2 diabetes mellitus is responsible for over 90% of the overall
cases. Treatment of this form of the disorder involves changes in
lifestyle and the use of oral antidiabetics [3], which, as it can be
seen from the rapidly growing number of affected people, is far
from being the solution. Novel therapeutic options have to be
considered, including the use of phytotherapeutics as alternative or
complementary agents which may crucially improve the life
quality of the patients.
The leaves and root bark of the white mulberry tree (Morus alba
L.) are known worldwide as sources of phytotherapeutics, which
have traditionally been used for the treatment of conditions related
to type II diabetes. A large number of in vivo animal [4–9] and
human studies [10–13] supported the anti-diabetic activity of
various mulberry preparations. Many different types of constitu-
ents have been linked to the anti-diabetic activity of mulberry
drugs, according to the followings:
1) Several iminosugars (or piperidine alkaloids) including 1-
deoxynojirimycin were isolated from mulberry leaves, root
bark and fruits [14–16], and found to inhibit a-amilase and
galactosidase. Among these iminosugars, nojirimycin deri-
vatives were the most effective ones. In fact, Miglitol
(DiastabolH), an oral antidiabetic drug in Europe, is
a synthetic derivative of 1-deoxynojirimycin, and both
Acarbose (GlucobayH) and Voglibose (BasenH) show simi-
larity to its structure.
2) Flavonoids and related constituents found in mulberry
species were also described for their anti-diabetes-related
effects: a concentrated flavonoid fraction from the root bark
of M. alba exerted protective effect on rat pancreatic b-cells
against streptozotocin (STZ) [17], and the leaves of a related
South-American mulberry species, M. insignis, were found to
contain two benzofurane derivatives that were active on
STZ induced diabetic rats [18]. On the other hand,
a partially purified flavone fraction of M. alba was found
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to activate a-glucosidase enzyme, which might lead to an
increase in the blood glucose level [19].
3) Polysaccharides from M. alba leaves exerted strong compet-
itive inhibition of a-glucosidase [19].
4) Glycopeptides isolated from the root bark of the white
mulberry tree showed insulin-like effect on experimentally
induced diabetic rats [4,7].
5) An apolar, volatile-oil like fraction of a hot water extract (i.e.
tea) of M. alba leaves was found to increase the in vitro glucose
consumption of adipocytes, and several phenyl-propane
derivatives including cinnamic acid were identified in the
fraction by means of GC-MS [20].
6) Ecdysteroids (20-hydroxyecdysone and inokosterone [21])
might also contribute to the anti-diabetic activity of
mulberry leaves, as these compounds can enhance tissue
sensitivity to insulin in rats when applied per os [22].
Despite (or exactly due to) the richness of M. alba leaves in
various constituents exerting anti-diabetic activity, an overview on
the relative importance of the individual compounds regarding the
complex anti-diabetic effect is not available in the literature.
However, such evaluation would be very important for a rational
standardization of mulberry products. In view of the scientific
literature, currently the iminosugars seem to be held the most
important active constituents of mulberry leaves. These com-
pounds lack a UV absorbing cromophore group, which makes
them less convenient marker compounds: most typically sophis-
ticated HPLC-MS techniques are suggested to their determination
[23,24].In our preliminary experiments [25], we have found high
amounts of chlorogenic acid, rutin and isoquercitrin present in
a 70% ethanol extract of the white mulberry leaves, which extract
was active in vivo; structures of these three compounds are shown in
Figure 1.
Considering that 10 mg/kg of chlorogenic acid was previously
found to exert significant hypoglycaemic activity on non-neonatal
streptozotocin induced diabetic rats [26] and rutin has also been
described for its hypoglycaemic activity at a dose of 25 mg/kg on
such a rat model [27], these compounds might significantly
contribute to the overall anti-diabetic action of the extract. Results
of the investigation of this hypothesis are described and discussed
in the present paper.
Results and Discussion
STZ is a natural substance specifically toxic to pancreatic b cells.
For this reason it is widely utilized to induce diabetes in mice and
rats. The characteristics of the developing diabetes are fundamen-
tally determined by the age of the animal. A single or repeated
treatment of adult rats results in a sharply and seriously elevated
plasma glucose level accompanied by polyuria and polydipsia, and
the correction of hyperglycemia requires parenteral insulin
treatment. This state shares the characteristics of insulin-de-
pendent diabetes mellitus (IDDM) and is therefore the intervention
of choice when hyperglycemia-induced structural or functional
deviations are to be studied [28]. Although the high plasma
glucose level is hard to be modified by orally administered agents,
this state (IDDM) is frequently but inappropriately considered as
an experimental model of non-insulin dependent diabetes mellitus
(NIDDM).
On the other hand, NIDDM can be elicited by a single
intraperitoneal STZ treatment of neonatal rats [29,30]. At 8–
10 weeks of age and thereafter, rats show nearly normal fasting
but substantially elevated postprandial blood glucose levels. It is
important to mention, that due to the nearly normal fasting blood
glucose levels, the effect on the postprandial blood glucose levels
can only be utilized as a measure of bioactivity in this model.
Although this certainly introduces the variable of food intake that
can influence the results, the overall conditions are more similar to
the situation in humans, and, as a practical aspect, the design of
fasting periods during a long-term experiment also becomes
unnecessary. Therefore, this approach provides a convenient
model of NIDDM [31], and it was used in the present study.
Moreover, our preliminary experiments also showed that the 70%
ethanol extract of mulberry leaves is active on this model [25].
A quantitative determination of the three main UV active
constituents, previously identified as chlorogenic acid (1), rutin (2)
and isoquercitrin (3), was performed from the crude, 70% ethanol
extract. Three independently measured samples of the extract
were analyzed by diode-array detected (DAD) high-pressure liquid
chromatography (HPLC). The two UV chromatograms used for
the quantitative determination, as well as the results of the peak
purity testing for the peaks of compounds 1–3 are presented in
Figure 2.
Peak purity testing is a built-in feature of the chromatographic
software ChromNAV, and is performed on the basis of a systematic
comparison of the UV spectra in a previously defined wavelength
range within the peak. This gives a purity distribution map that
can be displayed graphically as shown in Figure 2B. As a purity of
over 99.9% was found for over 95% of each peak area, and
practically all remaining peak areas possessed purities between
99.0 and 99.9% in the selected wavelength ranges, it can be
concluded that very good detection selectivities were achieved for
the three compounds of interest.
Calibration data for the three compounds are shown in Figure 3.
For chlorogenic acid and rutin, a very good linearity of the
calibration curves was found. Linearity was also tested using strict
statistical criteria at all data points, by evaluating the differences
between the mean and the actual values of peak area divided by
the sample amount. In case of a very good linearity these
difference values should not be higher than 5% for any of the data
points. In case of isoquercetrin, three out of nine data points
showed differences in the range of 5.68–6.83%, when the mean
Figure 1. Structures of chlorogenic acid (1), rutin (2) and isoquercitrin (3).
doi:10.1371/journal.pone.0050619.g001
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and the actual values of peak area divided by the sample amount
were compared, which still represents an acceptable linearity of
the calibration curve. Therefore, injected amounts of the three
samples to be analyzed were chosen in a way that each peak area
of compounds 1–3 falls in the region of its calibration curve, where
data points passed the linearity testing criteria (i.e. less than 5%
difference). Dashed frames in Figure 3C illustrate the ranges of the
calibration points where each compound of interest was de-
termined.
Calculated amounts and standard deviations for the three
compounds of interest present in the extract were as follows:
3.5860.06% for chlorogenic acid, 1.9660.03% for rutin and
1.2060.02% for isoquercitrin.
The animal experiments were designed based on the results of
the quantitative analysis: anti-diabetic activity of the mulberry leaf
extract was tested in doses of 250 and 750 mg/kg, and compounds
1–3 were tested in doses corresponding to the amounts present in
such doses of the extract. Activity testing of a mixture of the three
compounds in a ratio corresponding to that present in the extract
was additionally attempted. Unfortunately, this combination study
did not lead to any conclusive results; hence it is not discussed
here.
Blood samples were taken on the 4th, 8th and 11th days; results
are detailed in Table 1.
As a first approach, statistical analysis of the results was
performed by one-way ANOVA with Dunnett’s multiple com-
parison test, and statistically significant activities were found after
11 days of treatment. In order to decrease the possibility of false
negative results, further, planned comparisons between the treated
groups’ datasets and that of the control group were also performed
by using one-way ANOVA with separate Bonferroni post tests
utilizing uncorrected P values and confidence intervals. These
results are outlined in Figure 4.
After 11 days of treatment, the extract showed a significant,
dose related anti-diabetic activity on our in vivo model of type II
diabetes. By means of planned comparisons, chlorogenic acid and
rutin also showed significant anti-diabetic activity with tendencies
for dose dependency, which was not the case for isoquercitrin.
Since no fasting periods were scheduled for the animals, the
determined glucose levels indicate random plasma glucose values
and therefore they are closer to the represented human situation,
Figure 2. DAD fingerprint of an analyzed sample of mulberry leaf extract together with the chromatograms at l=326.3 nm (used
for determination of 1) and l=353.0 nm (used for determination of 2 and 3) and UV spectra of each compound (Fig. 2A), and
results of the peak purity testing for compounds 1–3 (Fig. 2B). In Fig. 2B, peak areas where purity was found over 99.9% (green) are
represented as mean of percentages 6 SD; n= 3.
doi:10.1371/journal.pone.0050619.g002
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i.e. not insulin dependent diabetes mellitus. Moreover, based on
the activity data, chlorogenic acid and rutin content seems to be
responsible for approximately half of the activity of the tested
extract in our experimental model. This finding is remarkable
considering the richness of mulberry leaves in various anti-diabetic
constituents, and it also suggests that these two compounds are
excellent markers for a simple and convenient UV-detection based
standardization procedure of anti-diabetic products prepared from
this drug. Nevertheless, we can also conclude that the a-
glucosidase activating effect of the flavonoid fraction previously
obtained from mulberry leaves [19] has, at least in case of rutin,
less biological significance than other mechanisms of action that
together lead to an anti-diabetic effect in vivo. On the other hand,
other flavonoids present in the drug might still have the potential
to exert a blood sugar level increasing activity via an increase of
glucose absorption. This would also mean, that in case of a well-
designed mulberry preparation for anti-diabetic purposes the high
chlorogenic acid and rutin content should be accompanied by low
levels of certain undesired flavonoid(s) – future research is needed
to clarify whether such criteria are necessary or not.
Conclusions
Our results can briefly be summarized as follows.
1. A significant, dose-dependent anti-diabetic activity was found
for the 70% aqueous ethanolic extract of Morus alba leaves on
our in vivo model of type II. diabetic rats.
2. An analitical method was developed for the rapid, selective
determination of three, potentially active, major constituents
(chlorogenic acid, rutin and isoquercitrin) of the extract by
HPLC-DAD.
3. Contribution of the three major constituents to the overall
activity was investigated, and a dose related activity was
Figure 3. Calibration curves and corresponding data for the three compounds of interest, chlorogenic acid (Fig. 3A), rutin (Fig. 3B)
and isoquercitrin (Fig. 3C). Inj: injected amount, PA: peak area, 6Diff(%): difference between the actual value of PA/inj and the averages of each
such value in the table, which difference should be less than 5%. Dashed frames in each data table represent ranges where corresponding peak areas
of the extracts were found when tested.
doi:10.1371/journal.pone.0050619.g003
Table 1. Plasma glucose levels in the different treatment
groups.
Groups Day 0 Day 4 Day 8 Day 11
Control 6.3260.41 4.9860.33 4.9260.17 5.4160.17
Glibenclamide 5.5260.39 4.3660.29 4.5760.12 4.6260.26*(P)
MA (250 mg/kg) 7.3160.80 5.3260.17 5.3660.36 4.3760.24*
MA (750 mg/kg) 5.6060.27 5.1760.25 5.4160.30 4.1760.22**
1 (9 mg/kg) 6.0860.48 4.8060.33 4.9760.42 5.0360.20
1 (27 mg/kg) 6.1160.41 5.0360.26 4.5260.37 4.6160.23*(P)
2 (5 mg/kg) 6.7961.41 5.2760.45 5.6460.32 4.7160.16*(P)
2 (15 mg/kg) 6.3660.39 5.3360.22 5.9060.21 4.6560.12*(P)
3 (3 mg/kg) 6.4860.81 5.1360.13 5.7660.49 4.8260.23
3 (9 mg/kg) 6.6460.67 5.5760.34 5.9160.32 5.1060.37
Results are shown as mean 6 SEM; Control: 0.25% of methylcellulose, MA:
Morus alba leaf extract, 1: chlorogenic acid, 2: rutin, 3: isoquercitrin; * and **:
p,0.05 and 0.01, respectively by one-way ANOVA followed by Dunnett’s
multiple comparison test, *(P): p,0.05 by one-way ANOVA followed by
Bonferroni post test with uncorrected P value and confidence interval, as
compared to the control group.
doi:10.1371/journal.pone.0050619.t001
Figure 4. Plasma glucose levels after 11 days of treatment,
where significant differences to the control group were found.
Results are shown as mean 6 SEM, G: glibenclamide; for further details
see Table 1 legend.
doi:10.1371/journal.pone.0050619.g004
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observed for chlorogenic acid and rutin but not for isoquerci-
trin. The two previous compounds were found to play an
important role in the anti-diabetic effect of mulberry leaves: ca.
half of the observed activity can apparently be explained by
their presence. Although testing the three compounds was also
attempted in combination, at this time no conclusion on the
presence or absence of synergistic effect can be made.
4. Based on the above, our analytical method can provide
a valuable tool and a reasonable alternative of the existing
methods for the quality control of mulberry products.
Materials and Methods
Ethics statement
The animals were treated in accordance with the European
Communities Council Directives (86/609/ECC). The experimen-
tal animal protocol satisfied the Guidelines for Animal Experi-
mentation approved by the Animal Experimentation Committee
of the University of Szeged (approval no: IV/01758–1/2008). Rats
were kept at 22 3uC; the relative humidity was 30–70% and
maintained on a 12 h light:12 h darkness cycle. The animals were
maintained on a standard rodent pellet diet (Charles-River
Laboratories, Isaszeg, Hungary) with tap water available ad libitum.
After the experiments, they were sacrificed by CO2 inhalation.
Field activity for collecting plant sample did not require a specific
permission, the location was neither privately-owned nor protected
in anyway, and no protected or endangered species were involved.
Plant material & Extraction
Morus alba leaves were collected near A´sotthalom, Hungary in
August, 2009. Botanical identification was done by A. Hunyadi,
and a voucher specimen (collection No. MA082009) was deposited
in the Institute of Pharmacognosy, University of Szeged, Szeged,
Hungary. Two kg of air-dried leaves were extracted with 70%
aqueous ethanol and evaporated to dryness under reduced
pressure at 50uC to yield 675.4 g of dried extract (MA).
Solvents and standards
Chromatographic solvents were purchased from Merck Che-
micals (Budapest, Hungary). Chlorogenic acid, rutin and iso-
quercitrin were purchased from Sigma-Aldrich (Budapest, Hun-
gary), ChromaDex (Irvine, CA, USA) and Extrasynthe´se (Genay,
France), respectively. These materials were used both as standards
for the quantitative determination and as pure compounds tested
in the bioassay.
HPLC analysis
A quantitative determination was performed for the main UV-
active and potentially anti-diabetic constituents, chlorogenic acid,
rutin and isoquercitrin by HPLC on a gradient system of two Jasco
PU2080 pumps connected to a Jasco MD-2010 Plus diode-array
detector (DAD). A Zorbax SB C-18 (5 mm, 4.66250 mm) column
was used with an aqueous acetonitrile gradient (10% smoothly
increasing to 23 in 17 min, keeping the same ratio till t = 25 min
and returning to the original composition) at a flow rate of 1 mL/
min. Both ACN and water contained 0.05% of TFA. DAD data
were collected from 210 to 400 nm, and each compound was
determined at its UV absorbance maximum: l= 326.3 nm
(chlorogenic acid) and l= 353.0 nm (rutin and isoquercitrin).
Three independently measured samples were analyzed (10.0, 10.2
and 11.9 mg), each dissolved in 1.00 mL of 50% MeOH, and
10 mL of solution was injected.
In order to investigate detection selectivity, peak purity tests
were also performed by systematically comparing all obtained UV
spectra between l= 300–400 nm (chlorogenic acid) and l= 350–
450 nm (rutin and isoquercitrin) within the peaks of interest.
Calibration curves were obtained from analyzing 10 mL of 0.1–
0.7 (7 data points), 0.05–0.6 (7 data points) and 0.05–0.7 (9 data
points) mg/mL solutions of chlorogenic acid, rutin and isoquerci-
trin, respectively. Standard linear regression was used for
calculating the regression coefficient (R2), and linearity of each
calibration curve was also tested by calculating the differences
between each peak area (PA) divided by the amount of analyte
injected and the mean of these values within the dataset. Linearity
was accepted when differences were found to be less than 65%.
In vivo bioassay
Newborn Sprague-Dawley rats (two days after birth) were
treated with 150 mg/kg streptozotocin intraperitoneally. The
animals were housed in plastic cages in a thermoneutral environ-
ment (2261uC). Eight weeks later, the animals were randomized
into different treatment groups (n = 6 or 7). Once a day, the
different groups were orally treated with extract (250 or 750 mg/
kg), chlorogenic acid (9 or 27 mg/kg), rutin (5 or 15 mg/kg) or
isoquercitrin (3 or 9 mg/kg) suspended in 0.25% of methylcellu-
lose; the dosing volume was 5 mL/kg for all treatments. Standard
food and tap water were freely available. Venous blood samples
from the tail were collected and plasma glucose concentration was
determined by means of glucose oxidase – peroxidase colorimetric
method on the 4th, 8th and 11th days of the treatment (Reanal
Finechamical Co, Budapest, Hungary). All the calculations and
statistical evaluation were performed by GraphPad Prism 5
(GraphPad Software, San Diego, CA, USA).
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